Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Morning Bell 3 March

Jessica Amir
March 3, 2020

Morning Bell 2 March

Jessica Amir
March 2, 2020

February Market Overview

Jessica Amir
February 28, 2020

Morning Bell 28 February

Jessica Amir
February 28, 2020

Morning Bell 27 February

Jessica Amir
February 27, 2020

Market Update 26 February

Jessica Amir
February 26, 2020

Morning Bell 25 February

Jessica Amir
February 25, 2020

Reporting season: Appen (ASX:APX)

Jessica Amir
February 24, 2020

Morning Bell 24 February

Paulina Peters
February 24, 2020

Weekly Wrap 21 February

Jessica Amir
February 21, 2020